Post-renal transplant hemolytic uremic syndrome following combination therapy with tacrolimus and everolimus

Balaji Pratap; Georgi Abraham; C N Srinivas; Shanmuga Bhaskar

Post-renal transplant hemolytic uremic syndrome following combination therapy with tacrolimus and everolimus

Saudi J Kidney Dis Transpl. 2007 Nov;18(4):609-12.

Authors

Balaji Pratap¹, Georgi Abraham, C N Srinivas, Shanmuga Bhaskar

Affiliation

¹ Sri Ramachandra Medical College and Research Institute, Chennai, India.

PMID: 17951952

Abstract

A 34-year old male renal transplant recipient developed thrombotic microangiopathy (Hemolytic Uremic Syndrome) in the early post-transplant period following combined immuno-suppressive therapy with tacrolimus and everolimus. The management consisted of discontinuation of tacrolimus and substitution with mycophenolate mofetil. His renal functions improved, the hematological abnormalities reversed and he continues to have good graft function one year later.

Publication types

Case Reports

MeSH terms

Adult
Biopsy
Drug Therapy, Combination
Everolimus
Graft Rejection / drug therapy*
Graft Rejection / pathology
Hemolytic-Uremic Syndrome / chemically induced*
Hemolytic-Uremic Syndrome / drug therapy
Hemolytic-Uremic Syndrome / pathology
Humans
Immunosuppressive Agents / adverse effects*
Immunosuppressive Agents / therapeutic use
Kidney Transplantation*
Male
Mycophenolic Acid / analogs & derivatives
Mycophenolic Acid / therapeutic use
Prodrugs
Sirolimus / adverse effects
Sirolimus / analogs & derivatives*
Sirolimus / therapeutic use
Tacrolimus / adverse effects*
Tacrolimus / therapeutic use

Substances

Immunosuppressive Agents
Prodrugs
Everolimus
Mycophenolic Acid
Sirolimus
Tacrolimus